See more : Kaman Corporation (KAMN) Income Statement Analysis – Financial Results
Complete financial analysis of Celcuity Inc. (CELC) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Celcuity Inc., a leading company in the Biotechnology industry within the Healthcare sector.
- Hanmi Financial Corporation (HAFC) Income Statement Analysis – Financial Results
- NHN KCP Corp. (060250.KQ) Income Statement Analysis – Financial Results
- Aavas Financiers Limited (AAVAS.BO) Income Statement Analysis – Financial Results
- Akelius Residential Property AB (publ) (AKEL-D.ST) Income Statement Analysis – Financial Results
- Luoniushan Co., Ltd. (000735.SZ) Income Statement Analysis – Financial Results
Celcuity Inc. (CELC)
About Celcuity Inc.
Celcuity Inc., a clinical stage biotechnology company, focuses on the development of molecularly targeted therapies for cancer patients in the United States. The company's CELsignia diagnostic platform uses a patient's living tumor cells to identify the specific abnormal cellular process driving a patient's cancer and the related targeted therapy for the treatment. Its drug candidate includes Gedatolisib, which selectively targets various class I isoforms of PI3K and mammalian target of rapamycin and focus on the treatment of patients with hormone receptor positive, HER2-negative, and advanced or metastatic breast cancer. The company is also developing CELsignia MP test, a qualitative laboratory developed test that measures HER2, c-Met, and PI3K signaling activity in breast and ovarian tumor cells. It had a license agreement with Pfizer, Inc. for the development and commercialization rights to Gedatolisib. Celcuity Inc. was founded in 2011 and is headquartered in Minneapolis, Minnesota.
Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
---|---|---|---|---|---|---|---|---|---|
Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Cost of Revenue | 142.77K | 210.92K | 303.24K | 385.59K | 339.00K | 223.04K | 104.70K | 73.06K | 58.38K |
Gross Profit | -142.77K | -210.92K | -303.24K | -385.59K | -339.00K | -223.04K | -104.70K | -73.06K | -58.38K |
Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Research & Development | 60.59M | 35.29M | 25.76M | 7.68M | 6.27M | 6.33M | 4.98M | 3.06M | 2.01M |
General & Administrative | 5.64M | 4.10M | 2.60M | 1.87M | 1.54M | 1.61M | 972.52K | 263.66K | 250.09K |
Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
SG&A | 5.64M | 4.10M | 2.60M | 1.87M | 1.54M | 1.61M | 972.52K | 263.66K | 250.09K |
Other Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Operating Expenses | 66.23M | 39.39M | 28.36M | 9.56M | 7.81M | 7.93M | 5.95M | 3.33M | 2.26M |
Cost & Expenses | 66.23M | 39.39M | 28.36M | 9.56M | 7.81M | 7.93M | 5.95M | 3.33M | 2.26M |
Interest Income | 2.45M | 1.13M | 13.26K | 82.11K | 446.10K | 448.83K | 152.88K | 18.02K | 268.00 |
Interest Expense | 0.00 | 2.11M | 1.26M | 120.00 | 159.00 | 111.00 | 451.66K | 0.00 | 0.00 |
Depreciation & Amortization | 142.77K | 210.92K | 303.24K | 385.59K | 339.00K | 223.04K | 104.70K | 73.06K | 58.38K |
EBITDA | -58.31M | -39.18M | -28.05M | -9.17M | -7.47M | -7.71M | -5.85M | -3.26M | -2.20M |
EBITDA Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Operating Income | -66.23M | -39.39M | -28.36M | -9.56M | -7.81M | -7.93M | -5.95M | -3.33M | -2.26M |
Operating Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Total Other Income/Expenses | 2.45M | -978.95K | -1.25M | 81.99K | 445.94K | 451.72K | -298.79K | 18.02K | 268.00 |
Income Before Tax | -63.78M | -40.37M | -29.61M | -9.47M | -7.36M | -7.48M | -6.25M | -3.31M | -2.26M |
Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Income Tax Expense | 0.00 | 978.95K | 959.12K | -385.47K | -338.84K | 451.83K | 48.18K | 0.00 | 0.00 |
Net Income | -63.78M | -41.35M | -30.56M | -9.09M | -7.02M | -7.48M | -6.25M | -3.31M | -2.26M |
Net Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
EPS | -2.69 | -2.68 | -2.28 | -0.89 | -0.69 | -0.74 | -0.84 | -0.49 | -0.36 |
EPS Diluted | -2.69 | -2.68 | -2.28 | -0.89 | -0.69 | -0.74 | -0.84 | -0.49 | -0.36 |
Weighted Avg Shares Out | 23.68M | 15.42M | 13.38M | 10.27M | 10.23M | 10.12M | 7.46M | 6.72M | 6.31M |
Weighted Avg Shares Out (Dil) | 23.68M | 15.42M | 13.38M | 10.27M | 10.23M | 10.12M | 7.46M | 6.72M | 6.31M |
Celcuity: Flying A Phase 3 Trial Right Under Your Nose
Celcuity To Participate in Jefferies Global Healthcare Conference
Celcuity Announces Pricing of Underwritten Common Stock Offering
Celcuity Inc. Announces Plan to Initiate a Phase 3 Clinical Trial for Gedatolisib as First-Line Treatment for HR+/HER2- Advanced Breast Cancer and Secures Approximately $62 Million Debt Financing
Celcuity Inc. (CELC) Q1 2024 Earnings Call Transcript
Celcuity Inc. Reports First Quarter Financial Results and Provides Corporate Update
Celcuity Inc. Schedules Release of First Quarter 2024 Financial Results and Webcast/Conference Call
Celcuity To Present at Upcoming Needham and Stifel Investor Conferences
Celcuity Inc. (CELC) Q4 2023 Earnings Call Transcript
Celcuity Inc. Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update
Source: https://incomestatements.info
Category: Stock Reports